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Abstract  
Background. New therapeutic approaches to improve cardiac contractility without severe 
risk would improve the management of acute heart failure. Increasing systolic sodium influx 
can increase cardiac contractility, but most sodium channel activators have proarrhythmic 
effects that limit their clinical use. Here, we report the cardiac effects of a novel positive 
inotropic peptide isolated from the toxin of the Black Judean scorpion that activates 
“neuronal” TTX-sensitive sodium channels. 
Methods and results. All venoms and peptides were isolated from Black Judean 
Scorpions (Buthotus Hottentotta) caught in the Judean Desert. The full scorpion venom 
increased left ventricular function in sedated mice in vivo, prolonged ventricular 
repolarization, and provoked ventricular arrhythmias. An inotropic peptide (BjIP) isolated 
from the full venom by chromatography increased cardiac contractility, but did neither 
provoke ventricular arrhythmias nor prolong cardiac repolarization. BjIP increased 
intracellular calcium in ventricular cardiomyocytes, and prolonged inactivation of the 
cardiac sodium current. Low concentrations of tetrodotoxin (200nM) abolished the effect of 
BjIP on calcium transients and sodium current. BjIP did not alter the function of Nav1.5, but 
selectively activated the brain-type sodium channels Nav1.6 or Nav1.3 in cellular 
electrophysiological recordings obtained from rodent thalamic slices. Nav1.3 (SCN3A) mRNA 
was detected in human and mouse heart tissue. 
Conclusion. Our pilot experiments suggest that selective activation of TTX-sensitive 
neuronal sodium channels can safely increase cardiac contractility. As such, the peptide 
described here may become a lead compound for a new class of positive inotropic agents.  
Key words. acute heart failure, sodium channel, inotropic agents, arrhythmia, 
pharmacotherapy
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Introduction  
Heart failure kills in equal proportions either by a critical loss of contractile cardiac function 
or by sudden  due to ventricular arrhythmias 1-3. Currently available inotropic agents 
(sympathomimetic agents, calcium sensitizers, or phosphodiesterase inhibitors) improve 
hemodynamic function at the price of potentially fatal proarrhythmic side effects and/or the 
deleterious consequences of chronic β-adrenoreceptor stimulation. Hence, inotropic therapy 
is confined to patients with severe, acutely decompensated heart failure treated on intensive 
care units 1, 2. An inotropic therapy without these side effects would clearly be desirable in 
the management of acute heart failure. 
 
Cardiac contraction is initiated by calcium release from the sarcoplasmic reticulum in 
cardiomyocytes. The trigger for calcium influx into the cell is an influx of sodium into the 
cardiomyocyte initiated through opening of voltage-gated sodium channels. Thereafter, 
opening of voltage-gated calcium channels, exchange of sodium and calcium via the sodium-
calcium exchanger, and calcium-activated calcium release from the sarcoplasmic reticulum 
accentuate this initial stimulus. Voltage-gated sodium channels, an evolutionary well-
preserved group of sarcolemmal transmembrane proteins, regulate voltage-dependent 
sodium influx and electrical excitability in neuronal and cardiac tissue 4. Activators of 
cardiac sodium channels are known to exert positive inotropic effects, but also cause 
arrhythmias 5. Cardiac sodium channels can be divided into TTX resistant (µM range) and 
TTX-sensitive (nM range) channel subtypes 4. The main isoform of the TTX-resistant sodium 
channels Nav1.5 is expressed predominantly in cardiomyocytes 4. Selective increase in the 
opening kinetics of Nav1.5 causes atrial fibrillation and heart failure 6, 7, and genetic variants 
in the Nav1.5 channel are associated with defibrillator shocks in heart failure patients 8. This 
may explain why activators of Nav1.5 are not used in patients with heart failure, despite their 
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positive inotropic effects 9. TTX-sensitive sodium channels, in contrast, are mainly expressed 
in mammalian brain and in skeletal muscle 4, 10, but also in T-tubules of cardiomyocytes close 
to calcium-releasing organelles 10, 11. Selective activation of TTX-sensitive sodium channels 
could hence provide a leverage to improve cardiac contraction without interfering with the 
electrophysiological function of cardiomyocytes. This has, however, never been formally 
tested. Here, we report about a peptide isolated from the venom of the Black Judean 
Scorpion, BjIP, which confers positive inotropy without proarrhythmic effects. This 
beneficial combination of effects appears to be mediated by selective activation of neuronal 
TTX-sensitive sodium channels (most likely Nav1.3 and/or Nav1.6). 
   
Methods 
All methods are explained in detail in the on-line supplement.  
 
Venom harvesting and isolation of the inotropic peptide BjIP. The full venom was 
harvested from Hottentotta judaicus scorpions. All venom and peptide fractions were 
harvested and prepared in Israel, and shipped to Muenster for functional and molecular 
analyses. 
 
Molecular characterization of BjIP. The inotropic peptide was characterized by Matrix-
Assisted Laser-Desorption Ionization-Time-Of-Flight Mass Spectrometry (MALDI-TOF MS). 
The N-terminal amino acid sequence (33 amino acids) was determined using Edman 
degradation. Total RNA isolated from the Black scorpion's venom gland was used for cDNA 
synthesis by the aid of SMART approach (Clontech, Park Tamar, Israel).  
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Real time quantitative PCR (qPCR) of Na+ channels in heart tissue. Total RNA was 
prepared from freshly dissected tissue by extraction with Trizol® reagent (RNeasy Lipid 
Tissue, Qiagen, Düsseldorf, Germany). Further details in supplemental methods. 
 
Dose selection for the full venom and the inotropic peptide. The limited access to 
BjIP required careful dose selection throughout the project. Preliminary experiments 
showed a positive inotropic effect of the full venom at 4µg/ml. Considering the expected 
weight contribution of BjIP to the protein content of the full venom (10%), we chose the 
concentrations given below for the initial functional assessment of the full venom and of BjIP 
(Table). Following the trabecular experiments demonstrating a positive inotropic effect of 
the BjIP at 1/10 of the initial concentration of BjIP, we reduced the concentration of BjIP for 
further cellular mechanistic experiments. 
 
Murine echocardiography. Cardiac function was measured during anesthesia on 
HP5500 and Vevo770 ultrasound microscopy systems (Visualsonics, Canada, 50-70 MHz 
transducers) in adult three months old CD-1 wild type mice 12. In brief, sedated animals were 
studied while spontaneously breathing. After establishing a stable physiological situation, 
left ventricular function was assessed in real-time by M mode echocardiography at baseline 
and after intraperitoneal injection of the full venom (40µg) or the inotropic peptide (BjIP, 
2µg). Cardiac contraction was monitored for 20 minutes after injection.  
 
Electrophysiological measurements in the isolated heart. Hearts of three months 
old wild type mice were isolated and retrogradely perfused (oxygenated modified Krebs-
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Henseleit solution, 37°C temperature, pH 7.4) on a modified Langendorff apparatus. 
Monophasic action potentials were recorded from the right and left ventricles of beating 
hearts 12, 13. The atrioventricular node was ablated to generate ventricular bradycardia. After 
a stabilization period of 10 minutes, spontaneous rhythm was observed, and ventricular 
pacing was performed at fix rates to assess ventricular action potential durations. The 
protocol was repeated after adding BjV or BjIP to the perfusate (Table). 
 
Recording of sodium current (INa) in murine cardiomyocytes. Ventricular 
cardiomyocytes were isolated and prepared for patch clamp experiments as described 14. 
Cells were exposed to BjIP (4 µg/ml) and TTX (200 nM) by a gravity driven fast application 
system (Warner, Holliston, USA). The inactivation time constant τ was derived from single 
exponential fits to the INa decay phase (Fitmaster, HEKA, Lambrecht, Germany). The total 
sodium influx was estimated by INa integration as the area under curve.  
 
Cardiomyocytes shortening and calcium transient measurements. Cell shortening 
was measured in electrically driven (0.5 Hz) mouse ventricular cardiomyocytes. Cells were 
isolated and mounted in tissue chambers, containing a modified Tyrode’s solution, for 
recording of cell shortening 15.  After a preequilibration period of 30 min, BjIP solution (0.4 
µg/ml) was superfused to the cardiomyocytes for 5 min. As a control, 200 nM TTX was 
applied, followed by BjIP. Cell shortening, time to peak tension, and relaxation time (90%) 
were continuously monitored during the measurement. For calcium transient measurements, 
indo1 fluorescence ratio (Ca2+) and cell shortening (Crescent Electronic Video Edge Motion 
Detector) were recorded simultaneously from isolated murine cardiomyocytes at room 
temperature during field stimulation at 0.5 Hz 16.  
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Single-cell electrophysiology in acute living brain slices. Brains were removed from 
decapitated rats and placed in an ice-cold, oxygenated solution. Acute living brain slices 
(280 µm thickness) containing the dorsal part of the lateral geniculate nucleus of the 
thalamus (dLGN) were cut on a vibratome (Leica VT1200, Wetzlar, Germany) and kept 
submerged in solution, and recording pipettes inserted into neuronal cells. Slices were 
continuously superfused with a bath solution. After establishment of the whole cell 
configuration, cells were superfused with a low Na+-solution. Signals were amplified (EPC-
10, HEKA) and digitally analyzed using Pulse. µ-Conotoxin PIIIA (µCtx, Alomone, 
Jerusalem, Israel), ProTX-II (ProTX, Alomone) which selectively inhibit distinct isoforms of 
voltage-dependent Na+ channels, or TTX (Tocris, Bristol, UK) were added directly into the 
bath. Recordings were obtained at baseline and during BjIP superfusion in identical cells. 
 
All functional experiments were approved by the Bezirksregierung in Münster, Germany, 
and conformed to the local and international regulation for experiments in animals.  
 
Statistical analysis. We compared categorical data using Fishers exact test. Numerical 
data were compared by two sided paired t tests (e.g. measurements before and after 
perfusion of BjIP or BJCV), Wilcoxon signed-rank tests. For multiple measurements data 
were analyzed by repeated measures analysis of variance followed by a multiple comparison 
procedure (Bonferroni t-test) if the overall test was significant. For thalamic recordings a 
one-sided (expected increase for BjIP; expected decrease for commercial blockers) test was 
used. Data were considered significantly different at p values <0.05. When data are 
displayed as boxplots, boxes and box limits indicate the data range mean, and standard 
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error. Whiskers indicate the minimum and maximum of the respective data. Individual 
measurements are shown in the boxplots as points. 
  
Results  
BjIP has inotropic effects without prolonging cardiac repolarization or 
provoking arrhythmias. The complete venom of Hottentotta judaicus (BjV), when 
injected intra-peritoneally into anesthetized albino CD1 mice (0.7-1.0 mg/mouse n=5) did 
neither kill nor affect locomotion. BjV (0.2 mg/mouse i.p.) increased ventricular contractility 
by 20-25% and caused ventricular arrhythmias (Fig1 a,b). When perfused in isolated, beating 
mouse hearts, BjV provoked ventricular arrhythmias and prolonged the ventricular action 
potential (Fig 1c-f). Reversed-phase HPLC chromatography identified an inotropic peptide. 
Intraperitoneal application of 20 µg BjIP increased contraction of the murine heart in vivo to 
a similar extent as the full venom (Fig 1a,b). In contrast to the full venom, BjIP did neither 
provoke ventricular arrhythmias when administered intraperitoneally in vivo (Figure 1a) nor 
during perfusion in the isolated heart (Fig 1c,d). Furthermore, BjIP did not prolong action 
potential duration in the isolated, beating heart (4 µg /ml BjIP, Fig 1e-g).  
 
The primary sequence and predicted tertiary structure of BjIP closely resemble 
scorpion venom long chain neurotoxins affecting the voltage-gated sodium 
channels. BjIP was sequenced and its tertiary structure modeled (Fig 2): The full sequence 
includes 63 amino acids of mature polypeptide, 19 amino acids of the signal peptide (red 
underline), 111 base pairs of untranslated nucleotides, and a polyadenylation site (black 
underline) – followed by 30 base pairs of poly A. Based on the molecular mass of the 
peptide, the last two amino acids of the mature peptide are cleaved (blue underline in Fig 
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2b). The modeled structure of BjIP resembles that of β-type insect toxins (Fig 2c,d), 
consistent with the transient contraction of Sarcophaga falculata blowfly larvae upon 
exposure to 20-50 ng BjIP /100 mg body weight (ED50 for flaccid paralysis 30-40ng/100mg 
body).  
 
The positive inotropic effects of BjIP are TTX-sensitive. BjIP superfusion enhanced 
contractility in right ventricular mouse trabecles (Fig. 3a) and increased contractility and 
intracellular calcium transients in paced mouse ventricular cardiomyocytes (Fig 3b-e). 
Furthermore, BjIP delayed inactivation of the cardiac sodium current without affecting peak 
current amplitude (Fig 3f-i). Nanomolar concentrations of TTX antagonized the effect of 
BjIP on contractility (Fig 3a), calcium transients (Fig 3d,e), and INa (Fig 3f-i).  
 
BjIP activates neuronal sodium channels. Fast inward currents in thalamocortical 
neurons17 indicated a sufficient voltage control and space clamp to assess Na currents (Fig. 
4a). Current amplitudes increased by application of BjIP (0.44 µg/ml; +16.1±8.4 %, n=7; Fig. 
4a,c). The inactivation time constant of INa was best fitted by a single exponential function at 
room temperature (Fig. 4b, e.g. τ = 4.9±0.8 ms  for the step to -30 mV, n=7). No changes in 
current decay were detected in the presence of BjIP τ = 5.0±0.5 ms (n=7; Fig. 4b). µCtx 18 
reduced INa by -19.4±3.9 % (n=4; Fig. 4f). In the presence of µCtx, BjIP increased INa 
amplitudes by 13.2±6.0 % compared to control (n=4; Fig. 4f). ProTx (0.5 µM 19) reduced INa 
amplitudes by -27.5±6.6 % (n=5; Fig. 4d, g). In the presence of ProTx, BjIP had no effect on 
current amplitudes (n=5; Fig. 4d, g). Additional application of TTX (1 µM) nearly completely 
inhibited INa in TC neurons (Fig. 4d). 
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Expression of TTX-sensitive Na channel genes in murine brain and heart and in 
human heart tissue. From the ten known NaV1 channel genes, mRNA of SCN1A (NaV1.1), 
SCN2A (NaV1.2), SCN3A (NaV1.3), SCN8A (NaV1.6), SCN11A (NaV1.9) and SCN7A (NaX) was 
detected in thalamic tissue (Fig. 4h). mRNA of the other Na+ channels were below detection 
limit in thalamus.   qPCR was used for heart tissue. Relevant expression of SCN3A mRNA, 
but not of SCN8A mRNA was detected in human and murine ventricular tissue, and slightly 
higher SCN3A mRNA levels were found in specialized conduction tissue (Purkinje fibers and 
AV node, Fig. 5). These findings together with the subtype specificity of µCtx and ProTx 
make NaV1.3 channels the most likely candidates for positive modulation by BjIP. 
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Discussion  
Main findings. Within the limitations of studying a biological toxin that had to be 
harvested and purified for each experiment, our findings suggest that selective activation of 
“neuronal”, TTX-sensitive sodium channels in the heart (most likely Nav1.3 channels) by a 
peptide isolated from the venom of Buthotus Hottentotta may be a novel therapeutic 
principle to increase cardiac contractility without proarrhythmic side effects. Further 
experiments are needed to validate our encouraging preliminary findings. 
 
Currently available positive inotropic agents modulate unspecific kinases in cardiomyocytes, 
such as protein kinase C, but also calcineurin or calcium-dependent calmodulin kinase II 
(CaMKII) 20, 21. These kinases increase cAMP levels in the myocardium and thereby increase 
calcium release from the sarcoplasmic reticulum, but also alter the function of the main 
cardiac sodium channel Nav1.5 by phosphorylation 21, and thereby increase cardiac 
contractility. Activators of the main cardiac sodium channel Nav1.5 increase contractility 5, 22. 
Activation of Nav1.5, however, also prolongs repolarization 5, 22 and provokes ventricular 
arrhythmias 23.  
 
TTX-sensitive sodium channels contribute to sodium influx and increased contractility in the 
heart: Approximately 25% of mammalian cardiac sodium channels are TTX-sensitive, and 
preferentially localized close to the T tubules 11.  Our own qPCR measurements confirm that 
SCN3A/Nav1.3 mRNA is present in human and mouse ventricular tissue (Figure 5), while 
SCN8a/Nav1.6 mRNA is not found in the heart, consistent with a recent report in rats 
(Figure 6 in 24). Insect toxins can have inotropic effects in large mammals 25, and nanomolar 
concentrations of TTX exert a negative inotropic effect (-20%) in beating guinea-pig hearts 
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10. It is noteworthy that a similar phenomenon, although less noticeable, can be seen in Fig. 
3d,e, where TTX (200 nM) reduces contractility slightly below control values.  
 
Similar to the Nav1.5 activators and to apelin 26, the full venom of the Hottentotta judaicus 
has inotropic effects, but also prolongs the ventricular action potential and provokes 
ventricular arrhythmias (Figure 1). BjIP, in contrast, increased contractility in vivo and in 
cardiomyocytes without proarrhythmic effects (Figure 1). Furthermore, the effect of BjIP was 
reversed by TTX (Figure 3), suggesting an action on TTX-sensitive cardiac sodium channels, 
i.e. Nav1.1, Nav1.2, Nav1.3, Nav1.4 , Nav1.6 or Nav1.7 4, 27, or alternatively spliced Nav1.5 sodium 
channels 28. Although we could not measure full I-V-relations due to limited amounts of 
BjIP, we have sufficient data so show that BjIP delays INa inactivation without altering INa 
amplitude. Our electrophysiological experiments in thalamic slices suggest that BjIP 
activates Nav1.3 and/or Nav1.6 (Fig. 4). Consistent with published reports 4, 11, 27, 29-31, we find 
expression of Nav1.3 channel mRNA in ventricular myocardium. Thus, it seems likely that the 
inotropic effect of BjIP is mediated by activation of Nav1.3, possibly initiating a localized 
increase in sodium close in the T tubules of cardiomyocytes 11 close to the sarcoplasmic 
reticulum, where even a small sodium influx can increase local calcium concentrations and 
facilitate calcium release from the sarcoplasmic reticulum 32. A similar alteration in local 
calcium homeostasis was proposed in multiple sclerosis where axonal injury is caused by 
increased Nav1.6 channels in demyelinated axons and alters sodium-calcium exchange 33. 
Alternatively, sodium influx close to the T tubules may synchronize excitation-contraction 
coupling, and thereby improve inotropy 10, 11. BjIP may also increase diastolic sodium load in 
the cell by providing additional substrate to the sodium-calcium exchanger through 
activation of Nav1.3 channels, as has been shown for the Nav1.5 opener veratridine 34. These 
possibilities deserve further experimental examination. Of note, Nav1.6 , but not Nav1.3 mRNA 
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expression is increased in response to pressure overload, rendering activation of Nav1.6 
channels relevant in hypertrophied and failing hearts 30. Thus, activation of Nav1.3 and/or 
Nav1.6 seems a promising new cardiac inotropic principle.  
 
Limitations. We performed the experiments over a period of several years using different 
preparations of the peptide, limited by the available amount of the purified peptide obtained 
from freely living scorpions collected in the Negev Desert. Our attempts to generate 
recombinant BjIP have so far not allowed us to obtain an adequately folded peptide in 
sufficient amounts 35. Clearly, recombinant BjIP would be desirable to perform experiments 
in large animal models and in failing hearts, and to provide unambiguous evidence that the 
observed effects were mediated by BjIP and not by contaminations. These limitations 
notwithstanding, our data suggest that selective activation of the neuronal, TTX-sensitive 
sodium channels, most likely including Nav1.3, is a promising target for the development of 
novel inotropic substances. 
 
Further research directions. Our observations invite further studies, e.g. examining the 
following issues: 1. Providing dose-response curves for the effect of BjIP on different Na 
channels; 2. Determining whether Nav1.3 is indeed the main molecular target mediating the 
effect of BjIP; 3. Investigating the effect of BjIP in failing hearts, where Na channel 
expression, calcium handling, metabolic state, and Na channel function may be altered; 4. 
Determining the effect of BjIP in ischemia-reperfusion models ; 5. Assessing whether BjIP 
may have a specific antiarrhythmic effect that could explain that cardiac APD and ventricular 
arrhythmias are not affected by BjIP.  
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Figure 1. BjIP increases cardiac contraction without affecting cardiac rhythm.  
a: Representative M mode echocardiographic tracings at baseline, after injection of the full 
venom of Buthotus Hottentotta (BjV, 200µg), and after injection of the inotropic peptide 
(BjIP, 20µg). White lines indicate left ventricular systolic and diastolic dimensions. The 
tracing after BjV injection shows ventricular arrhythmias. 
b: Mean fractional shortening at baseline and after injection of BjV (200µg, grey) and BjIP 
(20µg, black).  
c-f: Effects of BjV (20µg/ml) and BjIP (4µg/ml) on cardiac electrophysiology in the beating 
heart as assessed in contracting, Langendorff-perfused (37°C, modified Tyrode’ s solution) 
mouse hearts with simultaneous recording of right and left ventricular monophasic action 
potentials. Ventricular arrhythmias were assessed after AV nodal block.  
c: Example of a spontaneous polymorphic ventricular tachycardia during BjV perfusion.  
d: Number of hearts with (black bars) and without (white stacked bars) spontaneous 
arrhythmias at baseline, during BjV perfusion, and during BjIP perfusion.  
e: Representative monophasic action potential recordings at baseline (top), during perfusion 
with the full venom BjV (middle), and during perfusion with BjIP (bottom). BJV prolongs 
the ventricular action potential, BjIP does not.  
f: Mean action potential durations at 70% repolarization and 140 ms paced cycle length at 
baseline (left), during perfusion with the full venom BjV (middle, grey), and during perfusion 
with BjIP (right, black). BjV prolongs ventricular action potential duration. 
g: Mean action potential durations at baseline (dotted lines) and during BjIP perfusion 
(solid lines) at different repolarization levels (APD50, APD70, APD90) and different paced 
cycle lengths (80 – 140 ms, x axis) in isolated, beating mouse hearts (n=7 hearts, n=18-21 
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action potentials per mean data point). All values are given as mean and standard deviation.  
 
Figure 2: Isolation, sequence and modeled structure of BjIP. 
a: Fractionation of the BjV (75 mg) by reversed phase HPLC. Preparative column of RP-C18 
(Vydac, USA) equilibrated by DDW + 0.1% TFA and eluted by a linear gradient of 
acetonitrile + 0.1% TFA with a changed steepness (not shown). Fraction 21 contains BjIP. 
b: Amino acid sequence of BjIP (fraction 21) as deduced from the cDNA clone. Total RNA 
isolated from Black scorpion venom gland was analyzed by SMART (Clontech, USA). The full 
sequence contained 61 amino acids of mature polypeptide (predicted weight 6609 Dalton), 
19 amino acids of the signal peptide (red underline), 111 base pairs of untranslated 
nucleotide after the stop codon, and a polyadenylation site (black underline), followed by a 
long segment of 30 base pairs of poly A. Matrix-Assisted Laser-Desorption Ionization–Time-
Of-Flight (MALDI-TOFF) mass spectrometry of BjIP confirmed a 6609 Dalton component 
(duplicate measurement from two independent venom batches). 
c: Superimposition of BjIP and five β toxins of known 3D structure (pdb codes 1B7D, 1I6F, 
1I6G, 1NRA, 1NRB) on the Swiss-Model modeling server, displayed in color RMS PyMOL: 
Dark blue thinner lines represent strong homology, red thick lines diversity. 
d: Structure of BjIP (PyMOL). The reduced length of BjIPs alpha helix is due to the absence 
of two adjacent lysines.  
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Figure 3: BjIP increases cardiomyocyte contractility, increases intracellular calcium 
transient amplitude, and prolongs opening of TTX sensitive sodium channels  
a: BjIP increases force of contraction by 13% in mouse right ventricular muscle strips. 200 
nM TTX abolish the inotropic effect of BjIP. 
b: Representative simultaneous recording of calcium transients and cell shortening at 
baseline and during superfusion with BjIP (0.4 µg/ml). 
 c: Corresponding mean calcium transient amplitude and cell shortening (n=12/3). BjIP 
increases calcium transient and cell shortening amplitudes.  
d: Representative cell shortening at baseline, with BjIP, and with BjIP+ 200 nM TTX. 
e: Mean cell shortening is increased by BjIP. This effect is reversed by 200 nM TTX (n=7).  
f: Representative recordings of INa from the same adult ventricular mouse cardiomyocyte at 
baseline, with 4 µg/ml BjIP and with BjIP and 200 nM TTX.  
g : BjIP does not affect the peak current amplitude of INa 
h: BjIP prolongs inactivation of INa as illustrated by increased inactivation time constant τ.  
i: Increased total Na+ influx estimated as area under the curve (AUC) (f-i: n=2-6; *p<0.05 
vs. base). The BjIP effects on INa are abolished by 200 nM TTX. 
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Figure 4: BjIP effect on INa in thalamic neurons.  
a: Current-voltage relationship of INa under control conditions (open squares) and in the presence of 
BjIP (closed squares) in a thalamocortical neuron. Continuous lines indicate Boltzmann fits corrected 
for driving force to the data points. The cell was held at -60 mV before stepping to -90 mV for 2 s and 
eliciting INa by voltage steps of increasing amplitudes (-60 to -30 mV, 10 mV increment, 30 ms 
duration). 
b: Inactivation kinetics of INa were best fitted by a single exponential function (see inset) and not 
different between control and BjIP. 
c: Original traces of INa recorded from thalamic neurons of acute living rat brain slices under control 
conditions (base, black trace) and in the presence of BjIP (0.44 µg/ml, dark grey trace). 
d: Current traces under control conditions (base, black trace), during application of ProTx-II (ProTx, 
0.5 µM, light grey trace), in combination with BjIP (ProTx + BjIP, dark grey trace) and with 
tetrodotoxin (TTX, 1 µM, dashed black line) added to the extracellular solution. INa was elicited by 
voltage steps from -90 mV (2 s) to -30 mV (30 ms, see inset). 
e-g: Box plots of current amplitudes under different recording conditions (as indicated; * p<0.05, ** 
p<0.01). µCtx is a blocker NaV1.2, NaV1.4 and NaV1.7. The most likely subtypes activated by BjIP are 
underlined. pro-Tx is an inhibitor of NaV1.2, NaV1.3, NaV1.5, NaV1.6, NaV1.7 and NaV1.8. 
h:  mRNA expression of SCN1A (NaV1.1), SCN2A (NaV1.2), SCN3A (NaV1.3), SCN4A (NaV1.4), SCN5A 
(NaV1.5), SCN8A (NaV1.6), SCN9A (NaV1.7), SCN10A (NaV1.8), SCN11A (NaV1.9), SCN7A (Nax) in 
thalamic brain  tissue. DNA marker bands are located in the left margin. “x” indicate channels that are 
inhibited by µCtx or ProTx. 
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Figure 5: Expression of SCN3A, but not SCN8A mRNA in murine and human heart tissue. 
a: PCR showing detection of SCN3A and SCN5A mRNA in human heart and blood and in mouse heart 
tissue. SCN8A mRNA is not detectable in the heart, but is readily detected in human leucocytes. 
b: Mean expression levels of SCN3A (black), SCN5A (grey), and SCN8A (non detectable) mRNA in 
mouse ventricular tissue derived from qPCR. 
c: Mean expression levels derived from qPCR of SCN3A (black), SCN5A (grey, reference, set to 1), and 
SCN8A (not detected) mRNA in human heart tissue taken from different regions, i.e. atria, ventricles, 
sinus node, AV node, and Purkinje fibers.  
ΔCt-means were used to express mRNA expression normalized to SCN5A expression applying 2-
ΔΔCt-method. 
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Table: Concentrations of the full venom (BjV) and of the inotropic peptide (BjIP, 6609 Da 
estimated weight) used for functional assessment. All numbers rounded to 0.1µg/ml, where 
applicable 
 
  
Full venom 
(BjV) 
Ionotropic peptide 
(BjIP) 
 
in vivo 
Toxicity (i.p.) 200 µg 20 µg (3 µmol)  
inotropy, arrhythmias 
(echocardiography, i.p.) 40 µg 2 µg (300 nmol) 
 
perfused 
preparations 
arrhythmias, AP, perfused heart 20 µg/ml 4 µg/ml (600 nM)  
Na current, superfused cardiomyocytes - 4 µg/ml (600 nM)  
isolated trabecles - 0.4 µg/ml (60 nM)  
Ca transients, superfused 
cardiomyocytes 4 µg/ml 0.4 µg/ml (60 nM) 
 
thalamic slices - 0.4 µg/ml (60 nM)  
    
 
